Skip to main content

Table 4 Prognosis in 2 years after liver transplantation

From: A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

  MSC (N = 11) Rituximab (N = 11) P value
Survival rate no. (%) 9 (81.8%) 8 (72.7%) 1.000
Graft survival rate no. (%) 9 (81.8%) 8 (72.7%) 1.000
Acute rejection no. (%) 1 (9.1%) 3 (27.3%) 0.586
Biliary complications no. (%) 0 (0%) 5 (45.5%) 0.035a
Ischemia type biliary lesion no. (%) 0 (0%) 4 (36.4%) 0.090
Bile duct anastomotic stenosis no. (%) 0 (0%) 3 (27.3%) 0.214
Bile leakage no. (%) 0 (0%) 1 (9.1%) 1.000
Septic shock no. (%) 1 (9.1%) 9 (81.8%) 0.002b
Pulmonary infection no. (%) 0 (0%) 8 (72.7%) 0.001b
Biliary infection no. (%) 0 (0%) 1 (9.1%) 1.000
Splenic abscess no. (%) 1 (9.1%) 0 (0%) 1.000
Arteriostenosis no. (%) 1 (8.3%) 3 (27.3%) 0.586
De novo tumor no. (%) 0 (0%) 1 (9.1%) 1.000
  1. aP < 0.05, bP < 0.01
  2. Abbreviations: MSC mesenchymal stem cell